Older Coverage
stories 361–420 of 705SK Hynix Plunges 10% in Asian Tech Selloff
SK Hynix fell nearly 10% and Samsung dropped over 6% as Asian tech stocks tracked a Wall Street AI-name selloff, the second sharp chip-sector drop in the Korean chipmaker's shares in two weeks.
Vogenx Prices $68M IPO for Metabolic Drug
Vogenx Prices $68M IPO for Metabolic Drug
Vogenx priced 6.25M shares at $12 to raise roughly $68M net, funding development of mizagliflozin, an SGLT1 inhibitor for gastrointestinal and metabolic disorders, through 2028.
Braveheart Bio Prices $300M IPO for Heart Drug
Braveheart Bio Prices $300M IPO for Heart Drug
Braveheart Bio priced 18.75M shares at $16 to raise $300M on Nasdaq, funding its lead drug BHB-1893 for hypertrophic cardiomyopathy in the same week two other biotechs also priced.
Figma Stock Drops 16% Despite Revenue Beat
Figma Stock Drops 16% Despite Revenue Beat
Figma shares fell as much as 16.5% after Q2 revenue beat estimates at $370M but rising AI infrastructure costs and the departure of two senior executives overshadowed a raised full-year outlook.
SPAC Pipeline Grows With Two More Filings
SPAC Pipeline Grows With Two More Filings
Gravity Acquisition Corp continued toward its own listing and Alternus Clean Energy issued $14.28M of preferred stock ahead of a planned uplisting, extending the blank-check filing wave Pulse flagged earlier this week.
Why 217 IPOs Still Doesn't Mean the Window Is Open
Why 217 IPOs Still Doesn't Mean the Window Is Open
The US has produced 217 IPOs in 2026, up 6.9% year over year, and almost none of them are venture-backed technology companies -- which is why the count says nothing useful about exit liquidity.
AMD Beats Estimates, Stock Falls on Musk's Nvidia Bet
AMD Beats Estimates, Stock Falls on Musk's Nvidia Bet
AMD's Q2 results beat consensus and CEO Lisa Su guided to 80% server revenue growth in the second half, but shares fell after Elon Musk said SpaceX would commit fully to Nvidia chips for its AI infrastructure.
Goldman-Backed Attovia Prices IPO, Lists on Nasdaq
Goldman-Backed Attovia Prices IPO, Lists on Nasdaq
Attovia Therapeutics priced its IPO at $17/share, raising roughly $212.5M, and began trading on Nasdaq today under ATTO -- another test of whether biotech's IPO window is genuinely reopening.
Seven Blank-Check Deals Hit the Market in Three Days
Seven Blank-Check Deals Hit the Market in Three Days
Between August 3 and August 5, three SPACs priced at $10 a unit and four more filed or amended registration statements with the SEC -- the densest run of blank-check activity of the summer.
Uber Beats Q2 Bookings, Guides Q3 Below Estimates
Uber Beats Q2 Bookings, Guides Q3 Below Estimates
Uber's Q2 gross bookings of $58B topped estimates, but Q3 guidance for both bookings and EPS came in below consensus, sending shares down about 4%.
Attovia Prices $289M Nasdaq IPO at $17 a Share
Attovia Prices $289M Nasdaq IPO at $17 a Share
Attovia Therapeutics priced 17 million shares at $17 to raise $289M on Nasdaq under the ticker ATTO, the largest operating-company listing of the first week of August.
Uber Issues Weaker Q3 Outlook Despite Bookings Beat
Uber Issues Weaker Q3 Outlook Despite Bookings Beat
Uber's Q2 gross bookings beat estimates on World Cup travel demand, but Q3 bookings and earnings guidance came in below Wall Street's forecast, sending shares down more than 4% premarket.
Uber CEO Dismisses Reports of a Waymo Split
Uber CEO Dismisses Reports of a Waymo Split
Dara Khosrowshahi pushed back on reports that Uber and Waymo are heading for a breakup, on the same day Uber's stock fell on soft forward guidance and Zoox announced paid robotaxi rides in Las Vegas.
S&P 500, Stoxx 600 Both Hit Record Highs
S&P 500, Stoxx 600 Both Hit Record Highs
The S&P 500 closed at its first record high in two months and the Stoxx 600 touched an all-time high, both propelled by strong earnings and renewed AI-trade optimism despite this week's capex-driven sell-offs.
D-Wave Publishes a Quantum Error-Correction Advance
D-Wave Publishes a Quantum Error-Correction Advance
D-Wave published Nature research showing a fast, high-fidelity entangling gate for its dual-rail superconducting qubits, with simulations suggesting up to a tenfold cut in logical error rates per correction increment.
Robinhood Lists a Fund That Buys Y Combinator Stakes
Robinhood Lists a Fund That Buys Y Combinator Stakes
Robinhood Ventures Fund II is set to list publicly on August 13 at $25 a share, aiming to raise $200M so retail investors can indirectly back roughly 80 Y Combinator-linked private companies -- while paying Robinhood 2% and 20% carry.
Stoxx 600 Hits a Record as European Equities Rally

Stoxx 600 Hits a Record as European Equities Rally
Europe's benchmark index set an all-time high, extending a global equity rally that also carried the S&P 500 and Dow to records this week on strong earnings and easing oil prices.
SpaceX's $1T Dream Meets Its First Insider Lockup Test
SpaceX's $1T Dream Meets Its First Insider Lockup Test
Roughly 911.5 million SpaceX shares become eligible for sale as insider lockups expire this week, a real supply test for a stock already down nearly half from its June IPO peak.
SoftBank Jumps as Asia Tech Tracks AI Rally
SoftBank Jumps as Asia Tech Tracks AI Rally
SoftBank shares surged more than 10% as Asian tech stocks tracked a strong Wall Street rally, with Arm's chip royalty optimism and gains at SK Hynix and Samsung all contributing.
SoftBank Surges 14% as Asia Tech Rallies
SoftBank Surges 14% as Asia Tech Rallies
SoftBank jumped nearly 14% and the KOSPI and Nikkei both rose more than 3.6% as Asian tech stocks tracked Wall Street's record-setting AI-fueled session.
Pinterest Beats Q2, Falls 8% on Soft Q3 Outlook
Pinterest Beats Q2, Falls 8% on Soft Q3 Outlook
Pinterest topped Q2 revenue and EPS estimates, but shares fell more than 8% in after-hours trading after Q3 guidance came in below what investors wanted to see.
Pinterest Beats the Quarter, Falls 7% on Guidance
Pinterest Beats the Quarter, Falls 7% on Guidance
Pinterest beat Q2 revenue and user growth estimates, but shares fell 7% after the company guided to Q3 revenue growth decelerating to 13-15% amid intensifying ad competition from Instagram.
SpaceX Beats in First Earnings Report Since IPO
SpaceX Beats in First Earnings Report Since IPO
SpaceX posted $7.81B in Q2 revenue, beating estimates by 13%, but shares swung after AI infrastructure capex hit $15.83B for the quarter, far above what analysts expected.
Attovia Prices IPO as Biotech's Public Pipeline Fills Out
Attovia Prices IPO as Biotech's Public Pipeline Fills Out
Attovia Therapeutics priced its Nasdaq IPO at $17 a share while Latigo Biotherapeutics advances its own S-1, the latest signs that the biotech listing window is filling with genuine clinical-stage pipelines.
Lucid's Turnaround Bets on $1.4B in Savings and Robotaxis
Lucid's Turnaround Bets on $1.4B in Savings and Robotaxis
Lucid launched an operational reset targeting $1.4B in 2026 cash savings, leaning on its Uber- and Nuro-linked robotaxi program as one of four priorities meant to fix a widening quarterly loss.
Tesla's China Business Is Its Cash Cow and Its Risk
Tesla's China Business Is Its Cash Cow and Its Risk
Ars Technica examines how much of Tesla's profitability still runs through China, and how quickly domestic Chinese EV makers are taking the share that funds it.
Palantir Revenue Jumps 93%, Stock Surges 29%
Palantir Revenue Jumps 93%, Stock Surges 29%
Palantir posted $1.94B in Q2 revenue, raised full-year guidance to roughly $8.15B, and watched its stock climb 29% in a single session as US commercial revenue grew 149% year over year.
Latigo Sets Terms for a $272M Nasdaq IPO
Latigo Sets Terms for a $272M Nasdaq IPO
Latigo Biotherapeutics set terms for a $272M Nasdaq IPO under ticker LTGO, pricing 16M shares at $16-18 to fund late-stage trials of its non-opioid Nav1.8 pain drug, a rival to Vertex's Journax.
What Circle's Trading Multiple Means for Coinbase
What Circle's Trading Multiple Means for Coinbase
Circle's stock trades well below its post-IPO peak even with USDC's volume growing, and that public multiple is the most direct read available on how the market is now pricing Coinbase's own stablecoin-dependent revenue.
Robotics' IPO Pipeline: Who's Actually Ready
Robotics' IPO Pipeline: Who's Actually Ready
Figure AI at a private $39B valuation and China's Unitree pursuing a Shanghai STAR Market listing represent two very different paths to a robotics IPO -- and neither looks genuinely ready by the disclosure standards Cerebras and SpaceX have just set.
The Nuclear-Chip IPO Pipeline Nobody's Pricing In
The Nuclear-Chip IPO Pipeline Nobody's Pricing In
Valar Atomics at a $6B private valuation and OLIX at $3.3B are both explicitly infrastructure bets, not software -- and neither has a clear public comp set yet, which means whoever lists first effectively prices the entire category.
Cerebras, Three Months Public: The Scorecard
Cerebras, Three Months Public: The Scorecard
Cerebras went public in May at a $56.43B implied valuation, becoming the market's clearest test case for whether a pure-play AI chip challenger to Nvidia can hold a premium multiple once quarterly numbers replace private-market narrative.
Tech's Biotech IPO Window Is Quietly Reopening
Tech's Biotech IPO Window Is Quietly Reopening
While tech IPOs grab headlines, this week's actual new listings are almost entirely biotech -- a sign the broader IPO window is widening beyond the handful of AI mega-caps everyone's watching.
The Anthropic-OpenAI IPO Race, Scored
The Anthropic-OpenAI IPO Race, Scored
Anthropic confidentially filed for IPO first, at a $965B valuation on a $47B revenue run rate -- but OpenAI's IPO pipeline is also active, and the two companies are now effectively racing to define what an AI-lab public listing should look like.
SpaceX Reports First Earnings as a Public Company Tuesday
SpaceX Reports First Earnings as a Public Company Tuesday
SpaceX posts its first-ever quarterly results Tuesday after market close, with Wall Street modeling roughly $6.88B in revenue -- the first real test of the $1.4T valuation the market has been pricing on faith since June.
BlossomHill Files for $100M Nasdaq IPO in Cancer Drugs
BlossomHill Files for $100M Nasdaq IPO in Cancer Drugs
BlossomHill Therapeutics filed for a $100M Nasdaq IPO under ticker BLSM, adding an oncology-focused biotech with $257M in prior funding to a summer pipeline of clinical-stage listings led by J.P. Morgan, Leerink and Guggenheim.
Databricks' $188B Mark Gets a Retail-Adjacent Front Door
Databricks' $188B Mark Gets a Retail-Adjacent Front Door
Clear Street's new pre-IPO platform is opening accredited-investor access to $188B-valued Databricks through an SPV structure -- a preview of how late-stage AI names may get priced before they ever file an S-1.
Westinghouse's IPO Filing Is a Bet on AI's Power Problem
Westinghouse's IPO Filing Is a Bet on AI's Power Problem
Nuclear reactor supplier Westinghouse Electric confidentially filed for a US IPO, riding investor enthusiasm for nuclear power as Big Tech's AI datacenter buildout strains the grid.
Blue Owl-Backed Latigo Advances Nasdaq IPO Plans
Blue Owl-Backed Latigo Advances Nasdaq IPO Plans
Latigo Biotherapeutics filed an amended S-1 this week, advancing its Nasdaq IPO to fund a pivotal Phase 3 trial for its non-opioid pain drug ahead of the trial itself starting.
SpaceX's Earnings Week Is a Referendum on AI Valuations
SpaceX's Earnings Week Is a Referendum on AI Valuations
SpaceX's first public earnings report and a roughly $116 billion lockup unlock land the same week the stock sits about 20% below its IPO price -- a live test of how much AI-era enthusiasm public markets will still pay for.
Coinbase's Circle Renewal Is a Preview of Crypto's IPO Math
Coinbase's Circle Renewal Is a Preview of Crypto's IPO Math
Coinbase renewing its Circle revenue-sharing deal even as trading revenue fell 19% for a third straight quarter shows crypto public companies leaning on stable, subscription-like income to offset volatile trading revenue.
Neoclouds Are Quietly Lining Up Behind SpaceX for IPOs
Neoclouds Are Quietly Lining Up Behind SpaceX for IPOs
Nscale hiring Goldman Sachs and JPMorgan for a possible late-2026 IPO, on the heels of a $14.6 billion private valuation and a $1.65 billion Anyscale acquisition, is an early look at the neocloud sector's own path toward public markets.
Consumer IPOs Are Getting Crushed While Biotech Pops
Consumer IPOs Are Getting Crushed While Biotech Pops
Jersey Mike's opened 9% below its IPO price the same day Reformation traded flat, while Apnimed popped 37.5% days later -- public investors are rewarding unmet-need biotech and discounting mature consumer brands.
The AI Lab IPO Race Is Now a Profitability Contest
The AI Lab IPO Race Is Now a Profitability Contest
With OpenAI and Anthropic both racing toward IPOs targeting valuations near $1 trillion, and OpenAI's own leadership reportedly expecting Anthropic to list first, public-market readiness increasingly hinges on profitability trajectory rather than raw scale.
Unitree's IPO Gives Humanoid Robotics a Real Price Tag
Unitree's IPO Gives Humanoid Robotics a Real Price Tag
Unitree's Shanghai IPO, with secondary-market chatter running toward $14.8 billion against a $6.2 billion base, is about to give the humanoid-robotics sector its first transparent public price -- a sharp contrast to Figure's opaque $39 billion private mark.
Why Musk's SpaceX Shares Stay Locked Until 2027
Why Musk's SpaceX Shares Stay Locked Until 2027
Elon Musk and a select group of SpaceX insiders remaining locked out of this week's share unlock until mid-2027, while other pre-IPO holders can sell, is a founder-alignment signal other AI-scale IPO candidates may want to copy.
Coinbase's Third Straight Down Quarter, With a Twist
Coinbase's Third Straight Down Quarter, With a Twist
Coinbase revenue fell 19% to $1.22B in a third consecutive quarterly decline, yet the company posted a record 10.3% share of global crypto trading volume -- shrinking revenue and growing market share at the same time.
Muted Consumer IPO Debuts Are a Warning for the Tech Pipeline
Muted Consumer IPO Debuts Are a Warning for the Tech Pipeline
Reformation and Jersey Mike's both priced and debuted within days of each other with muted first-day performance, a real-time read on risk appetite that every AI-adjacent IPO waiting in the wings should be watching closely.
Unitree's IPO Subscription Opens August 10 -- What Changed
Unitree's IPO Subscription Opens August 10 -- What Changed
Unitree set public subscription for August 10 on its Shanghai STAR Market IPO, offering 40.45 million shares, with first-half 2026 revenue guidance implying 35.6-45.4% year-over-year growth.
SpaceX Moves to Buy 130,000 Acres of Louisiana Marshland
SpaceX Moves to Buy 130,000 Acres of Louisiana Marshland
SpaceX is set to acquire roughly 130,000 acres of marshland in southern Louisiana, a major post-IPO capital deployment that lands the same week as its first public earnings report and lockup unlock.
Eric Trump-Backed Space-Eyes Bets Defense Tech on a SPAC
Eric Trump-Backed Space-Eyes Bets Defense Tech on a SPAC
Space-Eyes, a counter-drone and geospatial intelligence company backed by Eric Trump, agreeing to go public through a $638 million merger with McKinley Acquisition Corp shows blank-check listings finding real traction in defense tech, not just robotics.
A $100M SPAC IPO Signals Blank-Check Issuance Is Back
A $100M SPAC IPO Signals Blank-Check Issuance Is Back
East West Ave Acquisition Corp pricing a $100 million IPO targeting fintech, digital assets and energy deals is a small but real signal that blank-check issuance -- not just SPAC mergers -- is picking back up in 2026.
The US Just Blacklisted Foreign Humanoid Robots
The US Just Blacklisted Foreign Humanoid Robots
The US added foreign-made humanoid and quadruped robots to the FCC's national-security Covered List just days before Unitree's Shanghai IPO, effectively closing off what would otherwise be China's largest addressable robotics market.
What Unitree's Shanghai Listing Means for US Investors
What Unitree's Shanghai Listing Means for US Investors
Unitree Robotics choosing Shanghai's STAR Market over a US listing for its IPO is a clear example of how US-China tensions are pushing China's most valuable AI and robotics companies to list at home, cutting off ordinary US investors from direct access.
SpaceX's $116B Lockup Unlock Is a Bigger Test Than Earnings
SpaceX's $116B Lockup Unlock Is a Bigger Test Than Earnings
Starting August 6, up to 911.5 million SpaceX shares -- worth roughly $116B -- become eligible for sale in a staggered release, a supply event that dwarfs the stock's current public float.
Robinhood Now Makes More Money on Predictions Than Stocks
Robinhood Now Makes More Money on Predictions Than Stocks
Robinhood now generates more revenue from prediction markets than from traditional stock trading, a structural shift in its business mix that public-market investors are still working out how to price.
Biotech IPOs Are Upsizing Mid-Roadmap in 2026
Biotech IPOs Are Upsizing Mid-Roadmap in 2026
Several of 2026's biotech IPOs have expanded their target raise between initial filing and pricing, a sign the sector's strong average return this year has pulled in enough demand that bankers are re-cutting deal size on the fly.
SpaceX Leads a Genuinely Crowded Public-Markets Earnings Week
SpaceX Leads a Genuinely Crowded Public-Markets Earnings Week
SpaceX's first public earnings report anchors an unusually dense week of public-market disclosures across space, fintech and crypto, giving investors a rare same-week comparison of how differently AI-era companies are actually monetizing.
Why Robotics Is Quietly Becoming the SPAC Market's Favorite Exit

Why Robotics Is Quietly Becoming the SPAC Market's Favorite Exit
Between Agility Robotics' $2.5B SPAC merger and Michael Klein's newest blank-check vehicle, 2026's SPAC revival is being built on capital-intensive robotics and infrastructure, not the last cycle's meme stocks.
SPACs Are Quietly Having Their Best Stretch Since 2021
SPACs Are Quietly Having Their Best Stretch Since 2021
Three SPACs priced or announced deals in one week -- Churchill Capital XIII, East West Ave, and Space-Eyes' merger vehicle -- a pickup in blank-check issuance overshadowed by this week's AI mega-rounds.
